Syndax Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SNDX Nasdaq 2830 syndax.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Syndax Pharmaceuticals, Inc.

3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal - Jun 23rd, 2026 5:55 am
Syndax Pharmaceuticals (SNDX) Is Up 5.2% After Strong All-Oral Revuforj SAVE Trial Data - What's Changed - Jun 13th, 2026 6:12 am
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026 - Jun 11th, 2026 5:03 am
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology - Jun 11th, 2026 5:00 am
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Jun 4th, 2026 2:01 pm
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes - Jun 4th, 2026 5:00 am
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data - Jun 2nd, 2026 2:01 pm
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026 - Jun 1st, 2026 5:00 am
Assessing Whether Syndax Pharmaceuticals (SNDX) Looks Undervalued After Recent Share Price Weakness - May 24th, 2026 2:10 am
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data - May 21st, 2026 3:01 pm
Syndax Announces Participation in Upcoming Investor Conferences - May 20th, 2026 5:00 am
Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential - May 14th, 2026 10:50 am
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition - May 12th, 2026 8:31 am
Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain Traction - What’s Really Shifting? - May 1st, 2026 5:12 pm
Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ... - May 1st, 2026 1:18 am
Syndax Pharmaceuticals Q1 Earnings Call Highlights - Apr 30th, 2026 8:42 pm
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates - Apr 30th, 2026 3:30 pm
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update - Apr 30th, 2026 2:01 pm
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026 - Apr 24th, 2026 5:00 am
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset - Mar 21st, 2026 6:20 pm